Skip to main content
Clinical Trials/NCT01384110
NCT01384110CompletedPhase 1

Efficacy of a Brown Seaweed Extract Rich in Polyphenols on Glycemic Response to Sucrose in Human

innoVactiv Inc.1 site in 1 country43 target enrollmentStarted: June 1, 2011Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Phase 1
Status
Completed
Enrollment
43
Locations
1
Primary Endpoint
Significant reduction in postprandial glycemia

Study Overview

Brief Summary

The primary endpoint of this trial will be to evaluate if a single administration in human of a lemon ice tea containing 500 mg of a polyphenol-rich algal powder is able to reduce postprandial glycemia and insulinemia.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Crossover
Masking
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Eligibility Criteria

Ages
18 Years to 60 Years (Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • •Healthy volunteer aged 18 to 60
  • •BMI between 20 and 30
  • •Non-smoking
  • •Using valid contraceptive method (women of childbearing age)

Exclusion Criteria

  • •Iodine allergy, or allergy to components of the test product or placebo or standard meal
  • •Use of dietary supplements for duration of study
  • •History of gastro-intestinal affections, anemia, major surgeries or surgeries of the stomach or digestive tract

Arms & Interventions

Brown Seaweed Lemon Tea

Experimental

Single administration of lemon tea containing 500 mg of brown seaweed powder and 50 g of sucrose

Intervention: Reduction of glycemic index of ingested foods (Dietary Supplement)

Placebo lemon tea

Placebo Comparator

Single administration of placebo lemon tea containing 50 g of sucrose

Intervention: Reduction of glycemic index of ingested foods (Dietary Supplement)

Outcomes

Primary Outcomes

Significant reduction in postprandial glycemia

Time Frame: Immediately after product administration (single use)

Significant reduction in postprandial insulinemia

Time Frame: Immediately after product administration (single use)

Secondary Outcomes

  • Frequency and severity of Adverse Events as a Measure of Safety and Tolerability(First administration up to 7 days after last administration)

Investigators

Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials